Quoin Pharmaceuticals (QNRX) widens Q2 loss but wins key FDA, patent milestones
Rhea-AI Filing Summary
Quoin Pharmaceuticals Ltd. reported second quarter 2026 results and multiple clinical and regulatory milestones across its rare dermatology pipeline. QRX003 for Netherton Syndrome received FDA conditional approval of the proposed brand name QYLEKI™, continued in pivotal-path development, and is supported by a new U.S. Notice of Allowance covering a combination treatment patent. The company also submitted the first-ever IND for Peeling Skin Syndrome, which the FDA subsequently cleared, enabling a planned Phase 2/3 study in pediatric and adult patients in the United States and Europe in the second half of 2026. Quoin’s topical rapamycin platform QRX009 is advancing toward clinical testing with planned investigator-led studies in several additional indications.
Quoin held approximately $10.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026 and expects this to fund operations into 2027. Net loss for the quarter was about $5.4 million, compared with $3.7 million in the prior-year quarter, driven mainly by higher research and development spending.
Positive
- FDA cleared IND for Peeling Skin Syndrome enabling the first company-sponsored Phase 2/3 study to start in 2H 2026.
- Conditional FDA approval of QYLEKI™ as the proposed brand name for QRX003 and new U.S. patent Notice of Allowance strengthen the Netherton Syndrome program and IP.
- QRX009 topical rapamycin platform is advancing toward clinical testing with multiple investigator-led studies planned in serious rare dermatologic indications.
- Cash, cash equivalents and marketable securities of about $10.8 million are expected by the company to fund operations into 2027.
Negative
- Quarterly net loss increased to approximately $5.4 million from $3.7 million in the prior-year quarter, reflecting higher operating expenses.
- Six‑month net loss widened to about $10.4 million from $7.5 million for the same period in 2025.
- Shareholders’ equity declined to $3.9 million at June 30, 2026 from $13.1 million at December 31, 2025, as accumulated deficit increased.
- Cash and investments decreased compared with year-end 2025, while current liabilities rose to $6.6 million from $5.5 million.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash and cash equivalents: $3,845,606
Investments: $6,954,476
Net loss (quarter): $5,371,042
+5 more
8 metrics
Cash and cash equivalents
$3,845,606
Balance sheet as of June 30, 2026
Investments
$6,954,476
Balance sheet as of June 30, 2026
Net loss (quarter)
$5,371,042
Three months ended June 30, 2026
Net loss (six months)
$10,368,777
Six months ended June 30, 2026
Research and development expense (quarter)
$3,627,168
Three months ended June 30, 2026
Current liabilities
$6,613,158
As of June 30, 2026
Shareholders’ equity
$3,932,671
As of June 30, 2026
Weighted average ADSs outstanding
2,832,915
Basic and fully diluted, quarter ended June 30, 2026
Key Terms
Orphan Drug Designation, Fast Track, Rare Pediatric Disease Designations, Notice of Allowance, +2 more
6 terms
Orphan Drug Designation regulatory
"QRX003 holds Orphan Drug Designation in the United States, the European Union, and Japan"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track regulatory
"along with Fast Track and Rare Pediatric Disease Designations from the FDA"
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
Rare Pediatric Disease Designations regulatory
"along with Fast Track and Rare Pediatric Disease Designations from the FDA"
A rare pediatric disease designation is an official label granted to an experimental drug or therapy aimed at treating serious illnesses that mainly affect children and are uncommon. It matters to investors because the designation often brings benefits such as faster review, financial incentives, or market exclusivity that can lower development risk and increase the potential commercial value—think of it as a priority pass and toolkit that can shorten and protect a company’s path to pediatric treatments.
Notice of Allowance regulatory
"the U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 18/428,570"
A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.
Investigational New Drug (IND) regulatory
"Quoin submitted the first-ever IND to the FDA for Peeling Skin Syndrome (PSS)"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
compassionate use program medical
"reported a positive clinical update from its ongoing Pediatric Compassionate Use Program"
A compassionate use program lets seriously ill patients access an experimental drug or treatment outside formal clinical trials when no approved options are available, acting like a special permission to try a promising medicine. It matters to investors because these programs can generate early real-world safety and effectiveness signals, affect demand and manufacturing needs, and influence regulatory and public perception—factors that can change a company’s near-term costs, risks and valuation.
Earnings Snapshot
Net loss (quarter): $5,371,042
quarter ended June 30, 2026
Net loss (quarter)
$5,371,042
higher loss than $3,695,938 in the prior-year quarter
Net loss (six months)
$10,368,777
higher loss than $7,508,117 for the six months ended June 30, 2025
Total operating expenses (six months)
$10,604,784
increased from $7,750,356 for the six months ended June 30, 2025
Research and development (six months)
$7,060,930
increased from $4,424,724 in the prior-year period
Cash, cash equivalents and investments
approximately $10.8 million
company expects this to fund operations into 2027
FAQ
What were Quoin Pharmaceuticals (QNRX) key clinical milestones in Q2 2026?
Quoin achieved FDA conditional approval of the QYLEKI™ brand name for QRX003, received a U.S. patent Notice of Allowance for a Netherton Syndrome combination treatment, and saw its first-ever IND for Peeling Skin Syndrome cleared to enable a Phase 2/3 study in 2H 2026.
How much cash did Quoin Pharmaceuticals (QNRX) have as of June 30, 2026?
As of June 30, 2026, Quoin held approximately $10.8 million in cash, cash equivalents, and marketable securities. The company states this cash position is expected to fund operations into 2027, supporting continued development of QRX003 and QRX009.
What net loss did Quoin Pharmaceuticals (QNRX) report for Q2 2026?
For the quarter ended June 30, 2026, Quoin reported a net loss of about $5.4 million, compared with approximately $3.7 million in the same quarter of 2025. The increase was mainly associated with higher research and development expenses.
How is Quoin Pharmaceuticals (QNRX) progressing QRX003 beyond Netherton Syndrome?
QRX003 is being expanded beyond Netherton Syndrome into Peeling Skin Syndrome, where Quoin submitted and obtained FDA clearance of the first-ever IND. A company-sponsored Phase 2/3 study in pediatric and adult PSS patients is expected to initiate in the second half of 2026.
What is Quoin Pharmaceuticals’ (QNRX) strategy for its QRX009 topical rapamycin platform?
Quoin is advancing QRX009 toward clinical testing, with investigator-led studies planned in indications including Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. The company also plans to submit an additional IND to the FDA before the end of 2026.
How did Quoin Pharmaceuticals’ (QNRX) operating expenses change in the first half of 2026?
For the six months ended June 30, 2026, total operating expenses were about $10.6 million, compared with $7.8 million a year earlier. The increase was driven primarily by research and development spending, which rose to approximately $7.1 million from $4.4 million.
AI-generated analysis. How Rhea-AI works. Not financial advice.
